New strategies in neuroprotection and neurorepair

Neurotoxicity Research

Volumn 21, Issue 1, 2012, Pages 49-56

  Antonelli, Marta C ^a   Guillemin, Gilles J ^b   Raisman Vozari, Rita ^c   Del Bel, Elaine A ^d   Aschner, Michael ^e   Collins, Michael A ^f   Tizabi, Yousef ^g   Moratalla, Rosario ^h   West, Adrian K ⁱ  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d FORP   (Brazil)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LOYOLA UNIVERSITY CHICAGO   (United States)

^g HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h INSTITUTO DE SALUD CARLOS III   (Spain)

ⁱ UNIVERSITY OF TASMANIA   (Australia)

Author keywords

Alcohol; Cannabinoids; Glia; Metallothionein; Neuroprotection; Oxidative stress

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMYLOID BETA PROTEIN; CANNABIDIOL; CANNABINOID; DRONABINOL; HEAVY METAL; METALLOTHIONEIN I; METALLOTHIONEIN II; NEUROTOXIN;

ALCOHOLIC BEVERAGE; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DRUG MECHANISM; GLIA CELL; HUMAN; HUNTINGTON CHOREA; MACROGLIA; MICROGLIA; NERVE CELL; NERVE DEGENERATION; NERVE REGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

CENTRAL NERVOUS SYSTEM; METALLOTHIONEIN; NERVE REGENERATION; NEUROGLIA; NEUROPROTECTIVE AGENTS; NEUROTOXINS; OXIDATIVE STRESS; SUBSTANCE-RELATED DISORDERS;

EID: 84856258181     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-011-9265-8     Document Type: Article

References (50)

1. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69(3):1196-1203 (Pubitemid 27364841)
2. Ambjorn M, Asmussen JW, Lindstam M, Gotfryd K, Jacobsen C, Kiselyov VV, Moestrup SK, Penkowa M, Bock E, Berezin V (2008) Metallothionein and a peptide modeled after metallothionein, EmtinB, induce neuronal differentiation and survival through binding to receptors of the low-density lipoprotein receptor family. J Neurochem 104(1):21-37. doi: 10.1111/j.1471-4159.2007.05036.x (Pubitemid 350265072)
3. Anstey KJ, Mack HA, Cherbuin N (2009) Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am J Geriatr Psychiatr 17(7):542-555. doi: 10.1097/JGP.0b013e3181a2fd07
4. Asanuma M, Miyazaki I, Ogawa N (2003) Dopamine- or l-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5(3):165-176
5. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Diaz-Hernandez M, Ruiz C, Sendtner M, Lucas JJ, de Yebenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Gines S, Kraus J, Fernandez-Ruiz J, Galve-Roperh I, Guzman M (2011) Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134(Pt 1):119-136. doi: 10.1093/brain/awq278
6. Brundin P, Melki R, Kopito R (2010) Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 11(4):301-307. doi: 10.1038/nrm2873
7. Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G (2000) Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2(2-3):293-310
8. Chung RS, Vickers JC, Chuah MI, West AK (2003) Metallothionein-IIA promotes initial neurite elongation and postinjury reactive neurite growth and facilitates healing after focal cortical brain injury. J Neurosci 23(8):3336-3342 (Pubitemid 36531975)
9. Chung RS, Leung YK, Butler CW, Chen Y, Eaton ED, Pankhurst MW, West AK, Guillemin GJ (2009) Metallothionein treatment attenuates microglial activation and expression of neurotoxic quinolinic acid following traumatic brain injury. Neurotox Res 15(4):381-389. doi: 10.1007/s12640-009-9044-y
10. Chung RS, Howells C, Eaton ED, Shabala L, Zovo K, Palumaa P, Sillard R, Woodhouse A, Bennett WR, Ray S, Vickers JC, West AK (2010) The native copper- and zinc-binding protein metallothionein blocks copper-mediated Abeta aggregation and toxicity in rat cortical neurons. PLoS One 5(8):e12030. doi: 10.1371/journal.pone.0012030
11. Collins MA, Neafsey EJ, Wang K, Achille NJ, Mitchell RM, Sivaswamy S (2010) Moderate ethanol preconditioning of rat brain cultures engenders neuroprotection against dementia-inducing neuroinflammatory proteins: possible signaling mechanisms. Mol Neurobiol 41(2-3):420-425. doi: 10.1007/s12035-010- 8138-0
12. Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 44(10):1787-1794. doi: doi: 10.1016/j.freeradbiomed.2008.03.005
13. Del-Bel E, Padovan-Neto FE, Raisman-Vozari R, Lazzarini M (2011) Role of nitric oxide in motor control: implications for Parkinson's disease pathophysiology and treatment. Curr Pharm Des 17(5):471-488
14. Dexter D, Wells FR, Lees A, Agid F, Agid Y, Jenner P, Marsden C (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389 (Pubitemid 19037600)
15. Dheen ST, Kaur C, Ling EA (2007) Microglial activation and its implications in the brain diseases. Curr Med Chem 14(11):1189-1197 (Pubitemid 46739320)
16. Dirnagl U, Simon RP, Hallenbeck JM (2003) Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26(5):248-254 (Pubitemid 36556155)
17. Dringen R, Hirrlinger J (2003) Glutathione pathways in the brain. Biol Chem 384(4):505-516. doi: 10.1515/BC.2003.059 (Pubitemid 36609167)
18. Glass C, Saijo K, Winner B, Marchetto C, Gage F (2010) Mechanisms underlying inflammation in neurodegeneration. Cell 140:918-934
19. Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57(4):338-342 (Pubitemid 28182632)
20. Granado N, Ares-Santos S, O'Shea E, Vicario-Abejon C, Colado MI, Moratalla R (2010) Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine. Neurotox Res 18(1):48-58. doi: 10.1007/s12640-009-9106-1
21. Granado N, Ares-Santos S, Oliva I, O'Shea E, Martin ED, Colado MI, Moratalla R (2011) Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis 42(3):391-403. doi: 10.1016/j.nbd.2011.01.033
22. Granado N, Lastres-Becker I, Ares-Santos S, Oliva I, Martin E, Cuadrado A, Moratalla R (in press) NRF2 deficiency potentiates Methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia
23. Hidalgo J, Aschner M, Zatta P, Vasak M (2001) Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 55(2):133-145 (Pubitemid 32722153)
24. Lehre KP, Levy LM, Ottersen OP, Storm-Mathisen J, Danbolt NC (1995) Differential expression of two glial glutamate transporters in the rat brain: quantitative and immunocytochemical observations. J Neurosci 15(3 Pt 1):1835-1853
25. Leung YK, Pankhurst M, Dunlop SA, Ray S, Dittmann J, Eaton ED, Palumaa P, Sillard R, Chuah MI, West AK, Chung RS (2010) Metallothionein induces a regenerative reactive astrocyte phenotype via JAK/STAT and RhoA signalling pathways. Exp Neurol 221(1):98-106. doi: 10.1016/j.expneurol.2009.10.006
26. Martin HL, Teismann P (2009) Glutathione-a review on its role and significance in Parkinson's disease. FASEB J 23(10):3263-3272. doi: 10.1096/fj.08-125443
27. Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 79(6):964-973. doi: 10.1124/mol.111.071290
28. Mitchell RM, Neafsey EJ, Collins MA (2009) Essential involvement of the NMDA receptor in ethanol preconditioning-dependent neuroprotection from amyloid-betain vitro. J Neurochem 111(2):580-588. doi: 10.1111/j.1471-4159.2009. 06351.x
29. Mitchell RM, Neafsey EJ, Campbell EM, Collins MA (2011) Synaptic NMDA receptor-linked peroxiredoxin pathway is upregulated by moderate ethanol preconditioning and mimicked by cruciferous neuroprotectant, D3T. Alcohol Clin Exp Res 35:240A
30. Narantuya D, Nagai A, Sheikh AM, Masuda J, Kobayashi S, Yamaguchi S, Kim SU (2010) Human microglia transplanted in rat focal ischemia brain induce neuroprotection and behavioral improvement. PLoS One 5(7):e11746. doi: 10.1371/journal.pone.0011746
31. Neumann J, Gunzer M, Gutzeit HO, Ullrich O, Reymann KG, Dinkel K (2006) Microglia provide neuroprotection after ischemia. FASEB J 20(6):714-716. doi: 10.1096/fj.05-4882fje (Pubitemid 46671191)
32. Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308(5726):1314-1318. doi: 10.1126/science.1110647 (Pubitemid 40746128)
33. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernandez-Ruiz J, Guzman M, Galve-Roperh I (2009) Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132(Pt 11):3152-3164. doi: 10.1093/brain/awp239
34. Peters R, Peters J, Warner J, Beckett N, Bulpitt C (2008) Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37(5):505-512. doi: 10.1093/ageing/afn095
35. Polazzi E, Monti B (2010) Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog Neurobiol 92(3):293-315. doi: 10.1016/j.pneurobio.2010.06.009
36. Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, De Bem AF, Latini A, Tasca CI, Farina M, Raisman-Vozari R (2011) The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease. Curr Pharm Des 17(5):489-507
37. Ramlochansingh C, Taylor RE, Tizabi Y (2011) Toxic effects of low alcohol and nicotine combinations in SH-SY5Y cells are apoptotically mediated. Neurotox Res. doi: 10.1007/s12640-011-9239-x
38. Rock RB, Peterson PK (2006) Microglia as a pharmacological target in infectious and inflammatory diseases of the brain. J Neuroimmune Pharmacol 1(2):117-126 (Pubitemid 44257487)
39. Sagara JI, Miura K, Bannai S (1993) Maintenance of neuronal glutathione by glial cells. J Neurochem 61(5):1672-1676 (Pubitemid 23317188)
40. Salazar J, Mena N, Hunot S, Prigent A, Alvarez-Fischer D, Arredondo M, Duyckaerts C, Sazdovitch V, Zhao L, Garrick LM, Nunez MT, Garrick MD, Raisman-Vozari R, Hirsch EC (2008) Divalent metal transporter 1 (DMT1) contributes to neurodegeneration in animal models of Parkinson's disease. Proc Natl Acad Sci USA 105(47):18578-18583. doi: 10.1073/pnas.0804373105
41. Salemi J, Obregon DF, Cobb A, Reed S, Sadic E, Jin J, Fernandez F, Tan J, Giunta B (2011) Flipping the switches: CD40 and CD45 modulation of microglial activation states in HIV associated dementia (HAD). Mol Neurodegener 6(1):3. doi: 10.1186/1750-1326-6-3
42. Saxena S, Caroni P (2011) Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 71(1):35-48. doi: 10.1016/j.neuron.2011.06.031
43. Sivaswamy S, Neafsey EJ, Collins MA, Sivaswamy S, Neafsey EJ, Collins MA (2010) Neuroprotective preconditioning of rat brain cultures with ethanol: potential transduction by PKC isoforms and focal adhesion kinase upstream of increases in effector heat shock proteins. Eur J Neurosci 32(11):1800-1812
44. Storck T, Schulte S, Hofmann K, Stoffel W (1992) Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci USA 89(22):10955-10959
45. Streit WJ (2006) Microglial senescence: does the brain's immune system have an expiration date? Trends Neurosci 29(9):506-510. doi: 10.1016/j.tins.2006.07.001 (Pubitemid 44291814)
46. Tourino C, Zimmer A, Valverde O (2010) THC prevents MDMA neurotoxicity in mice. PLoS One 5(2):e9143. doi: 10.1371/journal.pone.0009143
47. von Bernhardi R, Tichauer JE, Eugenin J (2010) Aging-dependent changes of microglial cells and their relevance for neurodegenerative disorders. J Neurochem 112(5):1099-1114. doi: 10.1111/j.1471-4159.2009.06537.x
48. West AK, Chuah MI, Vickers JC, Chung RS (2004) Protective role of metallothioneins in the injured mammalian brain. Rev Neurosci 15(3):157-166 (Pubitemid 39050279)
49. Yenari MA, Kauppinen TM, Swanson RA (2010) Microglial activation in stroke: therapeutic targets. Neurotherapeutics 7(4):378-391.
50. Yin X, Knecht DA, Lynes MA (2005) Metallothionein mediates leukocyte chemotaxis. BMC Immunol 6:21. doi: 10.1186/1471-2172-6-21 (Pubitemid 41418983)